UK Introduces Chickenpox Vaccine for Children

In a significant health development, young children in the UK will now have access to chickenpox protection through the NHS. This new option is part of a vaccine that combines the existing MMR jab, already offered at 12 and 18 months to protect against measles, mumps, and rubella. Families with children up to six years old can also catch up on doses when invited.

Experts are optimistic about the new combined vaccine, known as MMRV, where “V” stands for varicella, the medical term for chickenpox. They believe it will greatly reduce the number of families affected by chickenpox annually and will help prevent severe cases.

Prior to this, parents needed to spend up to £200 for private vaccines to safeguard their children from the illness.

Details on the New Vaccine Rollout

Starting January 1, the MMRV vaccine will be included in the standard vaccination schedule for children in England, Wales, and Northern Ireland. Scotland has also announced it will begin its rollout in early January.

Chickenpox is quite prevalent among young children, characterized by an itchy, spotty rash that blisters before scabbing over. The illness can be uncomfortable and often causes fever and muscle aches, leading to children missing a week of school or nursery.

But, Dr. Gayatri Amirthalingam, a deputy director at the UK Health Security Agency, cautions that while chickenpox is usually mild, it can lead to severe complications, including hospitalization and, though rare, even death.

Complications from chickenpox may include bacterial infections of scabs, encephalitis (brain swelling), pneumonitis (lung inflammation), and in rare cases, stroke. Infants and adults face a higher risk of serious illness, with pregnant women being particularly vulnerable due to potential complications affecting both the mother and unborn child.

Personal Experiences Highlight Risks

Maria Horton shared a personal story about her daughter, Beth, who, at just two-and-a-half years old, suffered a stroke after contracting chickenpox. “She collapsed and her arm and leg went all floppy, then she started to have a seizure,” Maria recounted. Beth now deals with multiple long-term effects, including the inability to use her right hand and chronic pain.

Maria expressed how she would have jumped at the chance to have the vaccine if it had been available then. “As a mother, if you could go back and prevent something catastrophic, you absolutely would,” she said, emphasizing her desire to spare others from such pain.

Dr. Claire Fuller, the national medical director for NHS England, described this initiative as a “hugely positive moment for children and families.” Health Secretary Wes Streeting encouraged all parents to take advantage of this vaccine, calling it a “historic milestone” for protecting children from a disease that leads thousands to hospitals annually.

The MMRV vaccine has been safely administered in countries like the U.S., Canada, Australia, and Germany for decades, resulting in significant decreases in chickenpox cases and related complications.

This vaccine has shown a high effectiveness rate of around 97% after two doses and offers long-lasting protection. The UK, in the past, has hesitated to implement a nationwide program, largely due to cost concerns and fears of increased shingles cases later in life. However, these concerns haven’t materialized in countries already using the vaccine.

Research indicates that chickenpox costs the UK £24 million annually in lost income and productivity; this vaccine rollout could potentially save the NHS £15 million each year in treatment costs.

For these reasons, the Joint Committee on Vaccination and Immunisation recommended introducing the MMRV vaccine into the NHS in November 2023.

Who is Eligible for the Vaccine?

The MMRV vaccine will replace the current MMR jab and will help protect against measles, mumps, rubella, and varicella (chickenpox). Children born after January 1, 2026, will receive automatic doses at 12 and 18 months.

There will be a catch-up program for older children based on their birth dates:

• Children born on or after January 1, 2025, will receive two doses at 12 and 18 months.
• Those born between July 1, 2024, and December 31, 2024, will receive doses at 18 months and three years and four months old.
• Children born between September 1, 2022, and June 30, 2024, will receive one dose at three years and four months.
• Lastly, children born between January 1, 2020, and August 31, 2022, will get a single dose later in 2026.

It’s worth noting that kids aged six or older by the end of 2025 won’t be eligible for the MMRV, as they likely have already had the chickenpox infection.

GP surgeries will be reaching out to families when the vaccinations are due, ensuring smooth access to this important health measure.